Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26662547 | 1.00 | PIK3CA (0.44) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL26662554 | 1.00 | PIK3CA (0.44) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL30584260 | 0.92 | PIK3CA (0.47) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL26662476 | 0.92 | PIK3CA (0.47) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL26662481 | 0.92 | PIK3CA (0.47) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL26867290 | 0.91 | PIK3CA (0.45) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL26861857 | 0.91 | PIK3CA (0.45) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL30742472 | 0.91 | PIK3CA (0.45) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL30742080 | 0.90 | PIK3CA (0.44) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL27132514 | 0.90 | PIK3CA (0.44) | PIK3CAAKT1AKT2AKT3PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885AKT1 15/4885AKT2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.